These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39081243)

  • 21. Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
    Zhang X; Devins K; Ko EM; Reyes MC; Simpkins F; Drapkin R; Schwartz LE; Yoon JY
    Gynecol Oncol; 2021 Jun; 161(3):762-768. PubMed ID: 33773808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of ER/PR expression in ovarian low-grade serous carcinoma.
    Escobar J; Klimowicz AC; Dean M; Chu P; Nation JG; Nelson GS; Ghatage P; Kalloger SE; Köbel M
    Gynecol Oncol; 2013 Feb; 128(2):371-6. PubMed ID: 23103384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.
    Hannibal CG; Vang R; Junge J; Kjaerbye-Thygesen A; Kurman RJ; Kjaer SK
    Gynecol Oncol; 2012 Jun; 125(3):655-60. PubMed ID: 22370600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.
    Hasby EA
    Tumour Biol; 2016 Apr; 37(4):4889-900. PubMed ID: 26526579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Serous ovarian tumors].
    Diebold J
    Pathologe; 2014 Jul; 35(4):314-21. PubMed ID: 24916775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells.
    Qiu X; Klausen C; Cheng JC; Leung PC
    Cell Death Dis; 2015 Aug; 6(8):e1864. PubMed ID: 26313915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TERT promoter methylation and protein expression as predictive biomarkers for recurrence risk in patients with serous borderline ovarian tumours.
    Losi L; Botticelli L; Garagnani L; Fabbiani L; Panini R; Gallo G; Sabbatini R; Maiorana A; Benhattar J
    Pathology; 2021 Feb; 53(2):187-192. PubMed ID: 33032810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas.
    Nougaret S; Lakhman Y; Molinari N; Feier D; Scelzo C; Vargas HA; Sosa RE; Hricak H; Soslow RA; Grisham RN; Sala E
    AJR Am J Roentgenol; 2018 Apr; 210(4):918-926. PubMed ID: 29489407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High Frequency of
    Ishibashi T; Nakayama K; Razia S; Ishikawa M; Nakamura K; Yamashita H; Dey P; Iida K; Kurioka H; Nakayama S; Otsuki Y; Ishikawa N; Kyo S
    Diagnostics (Basel); 2019 Dec; 10(1):. PubMed ID: 31892193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).
    Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
    J Ovarian Res; 2017 Jan; 10(1):7. PubMed ID: 28122595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The genomic trajectory of ovarian high-grade serous carcinoma can be observed in STIC lesions.
    Cheng Z; Ennis DP; Lu B; Mirza HB; Sokota C; Kaur B; Singh N; Le Saux O; Russo G; Giannone G; Tookman LA; Krell J; Barnes C; McDermott J; McNeish IA
    J Pathol; 2024 Sep; 264(1):42-54. PubMed ID: 38956451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
    Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
    BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
    Webb JR; Milne K; Kroeger DR; Nelson BH
    Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles.
    May T; Shoni M; Crum CP; Xian W; Vathipadiekal V; Birrer M; Rosen B; Tone A; Murphy KJ
    Gynecol Oncol; 2013 Mar; 128(3):488-92. PubMed ID: 23253401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.
    May T; Virtanen C; Sharma M; Milea A; Begley H; Rosen B; Murphy KJ; Brown TJ; Shaw PA
    Gynecol Oncol; 2010 Apr; 117(1):9-17. PubMed ID: 20117829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry.
    Ali RH; Kalloger SE; Santos JL; Swenerton KD; Gilks CB
    Int J Gynecol Pathol; 2013 Nov; 32(6):529-35. PubMed ID: 24071867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
    Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
    Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Analysis of High-Grade Serous Ovarian Carcinoma Exhibiting Low-Grade Serous Carcinoma and Serous Borderline Tumor.
    Kanno K; Nakayama K; Razia S; Islam SH; Farzana ZU; Sonia SB; Sasamori H; Yamashita H; Ishibashi T; Ishikawa M; Imamura K; Ishikawa N; Kyo S
    Curr Issues Mol Biol; 2024 Aug; 46(9):9376-9385. PubMed ID: 39329907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.
    Murali R; Selenica P; Brown DN; Cheetham RK; Chandramohan R; Claros NL; Bouvier N; Cheng DT; Soslow RA; Weigelt B; McCluggage WG
    Histopathology; 2019 Mar; 74(4):638-650. PubMed ID: 30565721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.